Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
February 2012, Vol 3, No 1
February 2012, Vol 3, No 1
VTE Prophylaxis during Chemotherapy Cost-Effective
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Venous thromboembolism (VTE) is a common cause of serious morbidity and mortality, and patients with cancer are at particular risk. “VTE has a substantial burden on the current US medical system.
Read Article
First Randomized Comparison of Catheter-Directed Thrombolysis versus Standard Care for DVT Prophylaxis
By
Neil Canavan
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
In the first comparative trial of its kind, the Catheter-Directed Venous Thrombolysis (CaVenT) study determined that treating a clot directly with the recombinant, antithrombotic agent alteplase reduced the frequency of postthrombotic syndrome (PTS) and improved long-term outcome in patients with proximal deep-vein thrombosis (DVT) compared with standard anticoagulation methods.
Read Article
First Cost Analysis of Long-Term Management of CML
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Few analyses to date have assessed the long-term costs associated with the management of chronic myeloid leukemia (CML). At ASH 2011, Shrividya Iyer, PhD, of Pfizer, presented results of a retrospective analysis performed by a group of researchers at Pfizer and the Eliassen Group that looked at information from the Thomson Reuters MarketScan Commercial Claims and Encounters Database, and the Medicare Supplemental Database.
Read Article
Next-Generation Proteasome Inhibitors Cause Less Peripheral Neuropathy
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
The first-generation proteasome inhibitor bortezomib changed the treatment paradigm of multiple myeloma. Data are now maturing for the next-generation agent carfilzomib, with US Food and Drug Administration approval expected soon. Several novel agents in this class are also in the pipeline.
Read Article
Investigational Blinatumomab Puts BiTE on Acute Lymphoblastic Leukemia
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
The novel agent blinatumomab more than doubled the complete response (CR) rate in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) compared with standard therapies.
Read Article
Ponatinib Overcomes Hard-to-Treat T315I Mutation in Patients with CML/ALL
By
Neil Canavan
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Preliminary data from the phase 2 PACE (Ponatinib Ph+ALL and CML Evaluation) trial show that ponatinib (Ariad Pharmaceuticals) can overcome the difficult-to-treat T315I mutation in patients with chronic myeloid leukemia (CML).
Read Article
A Large Study Sheds Light on the Cost of Managing NHL
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
A large, ongoing Canadian study provides an overview of the cost of managing non-Hodgkin lymphoma (NHL). “Our study provides total and stage-specific cost estimates for NHL, where attributable costs were 3- to 7-fold higher than those for non-NHL controls, and increased by stage,” said Pierre K. Isogai, BSc, of Sunnybrook Health Sciences Centre in Toronto.
Read Article
Guidelines for Molecular/Cytogenetic Tests Can Eliminate Overordering, Reduce Costs
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Instituting guidelines-based test ordering could lead to more effective, accurate, and complete diagnosis and monitoring of hematolymphoid malignancies, while reducing costs, according to hematopathologists at Vanderbilt University Medical Center, Nashville, who said that tests were frequently overordered by their hematologists.
Read Article
Significant Cost of Treating Myeloproliferative Neoplasms
By
Neil Canavan
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
A new cost analysis of the management of the 3 subtypes of myeloproliferative neoplasms (MPNs)—myelofibrosis, polycythemia vera, and essential thrombocythemia—shows that associated medical and pharmaceutical expenses for patients with these hematologic disorders in patients with cancer are 2 to 6 times that of matched patients without cancer.
Read Article
Serum-Based Immunoassay May Detect Pancreatic Cancer Early
GI Cancers Symposium
February 2012, Vol 3, No 1
San Francisco, CA—A serum-based enzyme immunoassay using the PAM4 antibody, combined with the serum marker CA19-9, detected stage I pancreatic cancer in nearly two thirds of patients analyzed in a study presented at the 2012 Gastrointestinal Cancers Symposium.
Read Article
Page 3 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma